<DOC>
	<DOCNO>NCT00835328</DOCNO>
	<brief_summary>The purpose study examine effect exendin- ( 9-39 ) glucose requirement maintain euglycemia infant congenital hyperinsulinism unresponsive medical therapy</brief_summary>
	<brief_title>Effect Exendin- ( 9-39 ) On Glucose Requirements To Maintain Euglycemia</brief_title>
	<detailed_description>This open label sudy examine effect exendin- ( 9-39 ) glucose requirement maintain euglycemia infant congenital hyperinsulinism unresponsive medical therapy determine therapeutic plasma level , plasma half life pharmacokinetics exendin- ( 9-39 )</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<criteria>Confirmed diagnosis congenital hyperinsulinism ( base clinical criterion : insulin , beta hydroxybutyrate , and/or free fatty acid plasma level time hypoglycemia , and/or glycemic response glucagon time hypoglycemia ) Age : birth 12 month Failure respond diazoxide ( defined failure maintain blood glucose octreotide ( defined failure maintain blood glucose ≥ 70 mg/dL without supraphysiologic rate glucose infusion &gt; 45 mg/Kg/min ) Evidence medical condition might alter result , include active infection , kidney failure , severe liver dysfunction , severe respiratory cardiac failure Current therapy time initiation study procedure medication affect glucose metabolism , high dose glucocorticoid , ßagonists , glucagon , diazoxide octreotide . Subjects eligible participate 4 hour glucagon discontinue , 24 hour last dose octreotide 72 hour last dose diazoxide , Subjects suspect BeckwithWiedemann syndrome syndromic form congenital hyperinsulinism .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hyperinsulinism</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>ATP- sensitive potassium channel ( KATP )</keyword>
</DOC>